
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Remove Advertising filter Advertising (2)
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (2) Apply Biologicals filter
- Remove Complementary medicines filter Complementary medicines (7)
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Listed medicines (2) Apply Listed medicines filter
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Remove Medical devices safety filter Medical devices safety (1)
- Remove Medicinal cannabis filter Medicinal cannabis (0)
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- OTC medicines (12) Apply OTC medicines filter
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Prescription medicines (5) Apply Prescription medicines filter
- Scheduling (55) Apply Scheduling filter
- Remove Therapeutic Goods Administration (TGA) filter Therapeutic Goods Administration (TGA) (2)
- Remove Therapeutic goods regulation filter Therapeutic goods regulation (2)
- (-) Remove Complementary medicines filter Complementary medicines
- (-) Remove Advertising filter Advertising
- (-) Remove Therapeutic Goods Administration (TGA) filter Therapeutic Goods Administration (TGA)
- (-) Remove Medicinal cannabis filter Medicinal cannabis
- (-) Remove Therapeutic goods regulation filter Therapeutic goods regulation
- (-) Remove Medical devices safety filter Medical devices safety
Proposed update to the evidence guidelines for listed medicines
Closed on 1 April 2022
Proposed improvements to the Therapeutic Goods Advertising Code
Closed on 18 June 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Methyl salicylate
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Lidocaine (lignocaine)
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Sedating antihistamines
Closed on 18 May 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Menthol
Closed on 18 May 2021
Fees and charges proposal 2021-22
Closed on 17 March 2021
Proposal to remove redundant processes for entering certain formulation information into a therapeutic goods application
Closed on 24 February 2021
IMDRF consultation: Proposed update to document on Post-Market Clinical Follow-Up Studies
Closed on 11 December 2020